During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 ...
Medpage Today on MSN3d
Combination Slows Metastatic CRC Progression Better Than Single ImmunotherapyMedian duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...
The phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in ...
Nivolumab plus ipilimumab prolonged PFS when compared to nivolumab alone in patients with MSI-H/dMMR unresectable or ...
A Peter Mac-led international clinical trial has shown adding an immunotherapy drug to the chemotherapy that patients receive ...
Researchers compare nivolumab as monotherapy or in combination with chemotherapy vs conventional treatment on overall survival and progression-free survival in patients with advanced unresectable ...
A phase 3 clinical trial has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved – almost ...
The investigational advanced melanoma combination therapy consisting of RP1 and nivolumab have a PDUFA action date of July 22 ...
Research has introduced daromun, therapeutic vaccines, and novel combinations for metastatic melanoma, reshaping the ...
Aethlon Medical, Inc. (Nasdaq: AEMD ), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious ...
Zacks Small Cap Research on MSN4h
AEMD Treats First Patient in Australian Safety, Feasibility & Dose-Finding Clinical Trial of HemopurifierAEMD Aethlon Medical (NASDAQ:AEMD) announced that the first patient in its Australian safety, feasibility and dose-finding clinical trial has been treated with the Hemopurifier. The trial is designed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback